Why does measuring glucose infusion rate matter for target validation in insulin sensitivity studies?

The glucose infusion rate quantifies the exogenous glucose needed to maintain euglycemia during insulin infusion, directly reflecting whole-body insulin sensitivity. This measurement allows researchers to assess whether a target modulation improves glucose disposal, providing functional validation beyond molecular binding or expression changes. It supports target confidence by linking mechanism to physiological outcome in a conscious, unrestrained model.

How does isolating the independent variable (insulin infusion rate) support discovery pipeline progression?

By maintaining a constant insulin infusion rate, the clamp isolates insulin as the independent variable, enabling attribution of glucose disposal changes to insulin action rather than confounding factors. This control allows clear evaluation of how test compounds or genetic modifications affect insulin-stimulated glucose uptake. It strengthens causal inference in target validation, aiding progression from hit to lead in metabolic drug discovery.

What do quantitative dependent variable measurements (glucose levels and infusion rates) enable in preclinical assessment?

Continuous monitoring of blood glucose and glucose infusion rate allows detection of steady-state conditions, defined as three consecutive readings within one millimolar over 30 minutes. The glucose infusion rate during steady state serves as a quantitative index of whole-body insulin sensitivity. These measurements enable dose-response analysis and comparison across treatment groups for go/no-go decisions.

Why do replication requirements (e.g., three consecutive glucose readings) matter for cross-functional collaboration?

Requiring three consecutive glucose readings within a narrow range ensures that steady state is genuinely achieved, reducing variability and increasing data reliability across experiments. This standardization supports comparability between laboratories, teams, and studies, which is essential for multi-site preclinical programs. Consistent criteria prevent false positives and enhance confidence in shared data for portfolio decisions.

What statistical analysis capabilities are required before implementing the hyperinsulinemic-euglycemic clamp in a discovery workflow?

Implementation requires the ability to calculate mean glucose infusion rates, assess variability (e.g., SEM or SD), and perform group comparisons using t-tests or ANOVA to determine statistical significance. Researchers must also be able to assess steady-state stability over time and detect outliers in glucose or infusion rate trajectories. These capabilities ensure that observed differences reflect true biological effects rather than measurement noise.

Bilinçli Rat hiperinsülinemik öglisemik Kelepçe

54.5K görüntüleme

33 kez atıf

11:12 dk

7 Şubat 2011

10.3791/2432-v

7 Şubat 2011

54.5K görüntüleme

Curtis C. Hughey¹ , Dustin S. Hittel¹^,² , Virginia L. Johnsen² , Jane Shearer¹^,²

¹Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Calgary, ²Faculty of Kinesiology, University of Calgary

Hiperinsülinemik öglisemik kelepçe insülin eylem değerlendirmesi için "altın standart". İnsülin, glukoz alımını teşvik sabit bir hızla doluyor. Bu düşüşün karşı aşılanmış eksojen glukoz miktarı insülin duyarlılığını göstermektedir. İşte prosedür bilinçli bir dizginlenmemiş sıçan yapılır.